BIOAGE Labs Inc
BIOA13.880USD
-0.200-1.42%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
497.60MMarket Cap
LossP/E TTM
More Details of BIOAGE Labs Inc Company
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
BIOAGE Labs Inc Info
Ticker SymbolBIOA
Company nameBIOAGE Labs Inc
IPO dateSep 26, 2024
CEOFortney (Kristen)
Number of employees62
Security typeOrdinary Share
Fiscal year-endSep 26
Address5885 Hollis Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108061445
Websitehttps://bioagelabs.com
Ticker SymbolBIOA
IPO dateSep 26, 2024
CEOFortney (Kristen)
Company Executives of BIOAGE Labs Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Chief Financial Officer
Chief Financial Officer
22.41K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
3.00K
--
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Eric Morgen, M.D.
Dr. Eric Morgen, M.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Dr. Kristen Fortney, Ph.D.
Dr. Kristen Fortney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Dr. Paul D. Rubin, M.D.
Dr. Paul D. Rubin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Vijay Pande, Ph.D.
Dr. Vijay Pande, Ph.D.
Independent Director
Independent Director
--
--
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Chief Financial Officer
Chief Financial Officer
22.41K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
3.00K
--
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Dr. Jean-Pierre (JP) Garnier, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Eric Morgen, M.D.
Dr. Eric Morgen, M.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Dr. Kristen Fortney, Ph.D.
Dr. Kristen Fortney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Andreessen Horowitz
9.02%
Sofinnova Investments, Inc
6.40%
Cormorant Asset Management, LP
5.97%
Adar1 Capital Management LLC
5.24%
VK Services, LLC
5.02%
Other
68.35%
Shareholders
Shareholders
Proportion
Andreessen Horowitz
9.02%
Sofinnova Investments, Inc
6.40%
Cormorant Asset Management, LP
5.97%
Adar1 Capital Management LLC
5.24%
VK Services, LLC
5.02%
Other
68.35%
Shareholder Types
Shareholders
Proportion
Venture Capital
28.09%
Hedge Fund
20.64%
Investment Advisor
12.20%
Investment Advisor/Hedge Fund
5.45%
Individual Investor
3.64%
Private Equity
2.24%
Research Firm
0.71%
Pension Fund
0.11%
Bank and Trust
0.09%
Other
26.82%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
187
24.89M
86.90%
+5.37K
2025Q3
186
24.88M
86.91%
+541.45K
2025Q2
172
24.31M
78.90%
+814.85K
2025Q1
149
24.62M
68.89%
-74.74K
2024Q4
130
24.06M
60.75%
-1.96M
2024Q3
72
25.47M
0.00%
+25.47M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Andreessen Horowitz
3.23M
9.02%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
2.30M
6.43%
--
--
Jun 30, 2025
Cormorant Asset Management, LP
2.14M
5.97%
-488.92K
-18.59%
Jun 30, 2025
Adar1 Capital Management LLC
1.94M
5.4%
+966.02K
+99.48%
Jun 30, 2025
VK Services, LLC
1.80M
5.02%
--
--
Apr 10, 2025
Longitude Capital Management Co., LLC
1.71M
4.77%
+400.00K
+30.52%
Apr 10, 2025
The Vanguard Group, Inc.
1.56M
4.34%
+859.89K
+123.25%
Jun 30, 2025
Tang Capital Management, LLC
1.60M
4.46%
--
--
Jun 30, 2025
Fortney (Kristen Ph.D.)
1.21M
3.38%
--
--
Apr 10, 2025
BlackRock Institutional Trust Company, N.A.
1.15M
3.21%
+497.75K
+76.28%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Innovator IBD Breakout Opportunities ETF
0%
iShares Morningstar Small-Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Fidelity Enhanced Small Cap ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Innovator IBD Breakout Opportunities ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BIOAGE Labs Inc?
The top five shareholders of BIOAGE Labs Inc are:
Andreessen Horowitz holds 3.23M shares, accounting for 9.02% of the total shares.
Sofinnova Investments, Inc holds 2.30M shares, accounting for 6.43% of the total shares.
Cormorant Asset Management, LP holds 2.14M shares, accounting for 5.97% of the total shares.
Adar1 Capital Management LLC holds 1.94M shares, accounting for 5.40% of the total shares.
VK Services, LLC holds 1.80M shares, accounting for 5.02% of the total shares.
Andreessen Horowitz holds 3.23M shares, accounting for 9.02% of the total shares.
Sofinnova Investments, Inc holds 2.30M shares, accounting for 6.43% of the total shares.
Cormorant Asset Management, LP holds 2.14M shares, accounting for 5.97% of the total shares.
Adar1 Capital Management LLC holds 1.94M shares, accounting for 5.40% of the total shares.
VK Services, LLC holds 1.80M shares, accounting for 5.02% of the total shares.
What are the top three shareholder types of BIOAGE Labs Inc?
The top three shareholder types of BIOAGE Labs Inc are:
Andreessen Horowitz
Sofinnova Investments, Inc
Cormorant Asset Management, LP
Andreessen Horowitz
Sofinnova Investments, Inc
Cormorant Asset Management, LP
How many institutions hold shares of BIOAGE Labs Inc (BIOA)?
As of 2025Q4, 187 institutions hold shares of BIOAGE Labs Inc, with a combined market value of approximately 24.89M, accounting for 86.90% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.01%.
What is the biggest source of revenue for BIOAGE Labs Inc?
In --, the -- business generated the highest revenue for BIOAGE Labs Inc, amounting to -- and accounting for --% of total revenue.
